Propylene carbonate ointment vehicle

Claim 2

An ointment comprising an ointment base consisting essentially of a. from 0.5 to 30 weight percent propylene carbonate; b. from 30 to 99.5 weight percent petrolatum, polysiloxane having a viscosity of from 0.5 to 10 6 centistokes, or mixtures thereof; c. compatible co-solvent, the concentration of which in combination with the propylene carbonate is from 0.5 to 70 weight percent; d. from 0 to 45 weight percent pharmaceutically acceptable surfactant; e. from 0 to 20 weight percent thickener; and f. from 0 to 25 weight percent penetrant in combination with a therapeutically effective amount of a propylene carbonate soluble medicament.

Claim 3

The ointment of claim 1 wherein the medicament is a topically active anti-inflammatory steroid.

Claim 4

The ointment of claim 2 wherein the steroid is a. a pregn-4-ene-3,20-dione having at each of positions C-1,2 and C-6,7, a single bond, double bond or group having the formula ##STR5## wherein R 11 and R 12 each is hydrogen, chloro or fluoro; at position C-6, hydrogen, methyl, fluoro or chloro; at position C-9, hydrogen, chloro, or fluoro; at position C-11, keto or ##STR6## wherein R 3 ' is hydrogen, hydroxy, chloro or fluoro; at position C-16, hydrogen, methyl, hydroxy or conventional hydrolyzable esters thereof, at position C-17α, hydrogen, hydroxy, conventional hydrolyzable esters thereof, or when taken together with C-16α, a group having the formula ##STR7## wherein R 6 is hydrogen or alkyl of up to 8 carbons, and R 7 is hydrogen, or alkyl or aryl having up to 8 carbons; and at position C-21, hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy, tetrahydrofuranyloxy, 4'-(lower)alkoxytetrahydropyran-4'-yloxy, lower alkoxy, lower cycloalkoxy, lower cycloalkenyloxy, chloro or fluoro; or b. a 2'-substituted-pregn-4-en-20-one-[3,2-c]pyrazole or a 1'-substituted-pregn-4-en-20-one-[3,2-c]-pyrazole having at the respective N-2' or N-1' positions, hydrogen, methyl, phenyl, chlorophenyl, fluorophenyl, methylphenyl, or methoxyphenyl, and having at C-6,7, a single bond, double bond or group having the formula ##STR8## wherein R 11 and R 12 each is hydrogen, chloro or fluoro; at position C-6, hydrogen, methyl fluoro or chloro; at position C-9, hydrogen, chloro or fluoro; at position C-11, keto or ##STR9## wherein R 3 ' is hydrogen, hydroxy, chloro or fluoro; at position C-16, hydrogen, methyl, hydroxy or conventional hydrolyzable esters thereof, at position C-17α, hydrogen, hydroxy, conventional hydrolyzable esters thereof, or when taken together with C-16α, a group having the formula ##STR10## wherein R 6 is hydrogen or alkyl of up to 8 carbons, and R 7 is hydrogen, or alkyl or aryl having up to 8 carbons; and at position C-21, hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy, tetrahydrofuranyloxy, 4'-(lower)alkoxytetrahydropyran-4'-yloxy, lower alkoxy, lower cycloalkoxy, lower cycloalkenyloxy, chloro or fluoro.

Claim 5

The ointment of claim 3 wherein the steroid is 6α,9α-difluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-acetoxypregna-1,4-diene-3,20-dione.

Claim 6

The ointment of claim 3 wherein the steroid is 6α,9α-difluoro-11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione.

Claim 7

The ointment of claim 3 wherein the steroid is 6α-fluoro-9α,11β-dichloro-16α,17α-isopropylidenedioxy-21-hydroxypregna-1,4-diene-3,20-dione.

Claim 8

The ointment of claim 3 wherein the steroid is 9α,11β-dichloro-6α,21-difluoro-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione.